ICR and Merck KGaA renew alliance in small-molecule cancer drugs

22 September 2023

The Institute of Cancer Research in London and German science and technology company Merck KGaA (MRK: DE) have renewed their strategic alliance in the discovery and development of new cancer drugs.

Scientists in the Centre for Cancer Drug Discovery at The Institute of Cancer Research (ICR) will work with researchers at Merck on a range of related projects, each of which aim to discover and develop new small-molecule inhibitors of a new class of cancer targets.

"The latest chapter in a partnership that has now lasted for almost 20 years"This multi-target, multi-year collaboration involves significant financial and staff commitments from both parties, including Merck funding nine full-time research posts at the ICR.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK